ArticleScientific reports2021
Delayed mortality, resistance and the sweet spot, as the good, the bad and the ugly in phosphine use.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 24 citations in OpenAlex.
- Resilience in Tribolium Castaneum Through Antioxidant Priming Under Phosphine-Induced Oxidative Stress.Molecular biotechnology · 2026Article
- Article
- Primary Investigation on the Synergistic Effects of Methyl Bromide and 1 °C Cold Treatment for Two-Spotted Spider Mite (Insects · 2025Article
- Assessment of Phosphine Resistance in Major Stored-Product Insects in Greece Using Two Diagnostic Protocols.Insects · 2024Article
- Chemical vs. Enzymatic Refining to Produce Peanut Oil for Edible Use or to Obtain a Sustainable and Cost-Effective Protector for Stored Grains againstFoods (Basel, Switzerland) · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphine is the most commonly used gas for fumigation for durable commodities globally, but there is still inadequate information regarding its efficacy in conjunction with proper concentration monitoring. In a series of bioassays, insect mortality after specific exposure intervals to phosphine in selected species was examined, as well as the appearance of the so called "sweet spot". The species that were tested were: Oryzaephilus surinamensis (L.), Tribolium castaneum (Herbst), Sitophilus oryzae (L.) and Rhyzopertha dominica (F.) with populations that had different levels of phosphine resistance. Evaluation was conducted by using the Phosphine Tolerance Test (PTT), with exposure of the adult stage for 15, 30, 60, 90, 150 and 300 min at 3000 ppm. At the end of these intervals (separate bioassays for each time interval), the insects were transferred to Petri dishes, in which recovery was recorded at different time intervals (2 h, 1, 2 and 7 days). The majority of susceptible populations of all species were instantly immobilized even in the shortest exposure period (15 min), in contrast with resistant populations that were active even after 300 min. After exposure to phosphine, populations and exposure time affected mortality of susceptible populations, whereas resistant populations recovered regardless of species and exposure time. Additional bioassays at the concentrations of 500, 1000, 2000 and 3000 ppm for 1, 3, 5, 20, 30 and 40 h showed the presence of the "sweet spot", i.e., decrease of mortality with the increase of concentration. In fact, for most of the tested species, the "sweet spot" appeared in 1000 and 2000 ppm at a 5-h exposure time, regardless of the level of resistance to phosphine. This observation is particularly important both in terms of the assessment of resistance and in the context of non-linear recovery at elevated concentrations, indicating the occurrence of strong hormetic reversals in phosphine efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.